Trivalent Combination Vaccine Induces Broad Heterologous Immune Responses to Norovirus and Rotavirus in Mice

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Tamminen, Kirsi ^a   Lappalainen, Suvi ^a   Huhti, Leena ^a   Vesikari, Timo ^a   Blazevic, Vesna ^a  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD GROUP ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; PROTEIN VP1; RECOMBINANT GAMMA INTERFERON; RECOMBINANT PROTEIN VP6; TRIPLE VACCINE; UNCLASSIFIED DRUG; VIRUS LIKE PARTICLE GII 4 VACCINE; VIRUS LIKE PARTICLE VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIVIRAL ACTIVITY; ARTICLE; BACULOVIRUS; CELL CULTURE; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS REACTION; DRUG DOSE COMPARISON; DRUG RECEPTOR BINDING; FEMALE; GENE EXPRESSION SYSTEM; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; IN VITRO STUDY; INSECT CELL; INTESTINE; MOUSE; NONHUMAN; NOROVIRUS; NUCLEOTIDE SEQUENCE; ROTAVIRUS; VACCINE PRODUCTION; VIRUS LIKE AGENT; VIRUS NEUTRALIZATION;

ANIMALS; ANTIBODIES, VIRAL; ANTIBODY FORMATION; CALICIVIRIDAE INFECTIONS; CROSS REACTIONS; HUMANS; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; NOROVIRUS; ROTAVIRUS; ROTAVIRUS INFECTIONS; VACCINES, COMBINED; VIRAL VACCINES;

EID: 84880786047     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0070409     Document Type: Article

References (67)

1. Dennehy PH, (2011) Viral gastroenteritis in children. Pediatr Infect Dis J 30: 63-64. doi:10.1097/INF.0b013e31820ad2ba. PubMed: 21173676.
2. Bucardo F, Lindgren PE, Svensson L, Nordgren J, (2011) Low prevalence of rotavirus and high prevalence of norovirus in hospital and community wastewater after introduction of rotavirus vaccine in nicaragua. PLOS ONE 6: e25962. doi:10.1371/journal.pone.0025962. PubMed: 22016794.
3. Puustinen L, Blazevic V, Salminen M, Hämäläinen M, Räsänen S, et al. (2011) Noroviruses as a major cause of acute gastroenteritis in children in finland, 2009-2010. Scand J Infect Dis 43: 804-808. doi:10.3109/00365548.2011.588610. PubMed: 21696253.
4. Koo HL, Neill FH, Estes MK, Munoz FM, Cameron A, et al. (2012) Noroviruses: The most common pediatric viral enteric pathogen at a large university hospital after introduction of rotavirus vaccination. J Pediatr Infect Dis Soc 2: 57-60.
5. Hemming M, Rasanen S, Huhti L, Paloniemi M, Salminen M, et al. (2013) Major reduction of rotavirus, but not norovirus, gastroenteritis in children seen in hospital after the introduction of RotaTeq vaccine into the national immunization programme in Finland. Eur J Pediatr. doi:10.1007/s00431-013-1945-3.
6. Atmar RL, Bernstein DI, Harro CD, Al-Ibrahim MS, Chen WH, et al. (2011) Norovirus vaccine against experimental human norwalk virus illness. N Engl J Med 365: 2178-2187. doi:10.1056/NEJMoa1101245. PubMed: 22150036.
7. Blazevic V, Lappalainen S, Nurminen K, Huhti L, Vesikari T, (2011) Norovirus VLPs and rotavirus VP6 protein as combined vaccine for childhood gastroenteritis. Vaccine 29: 8126-8133. doi:10.1016/j.vaccine.2011.08.026. PubMed: 21854823.
8. Velasquez LS, Shira S, Berta AN, Kilbourne J, Medi BM, et al. (2011) Intranasal delivery of norwalk virus-like particles formulated in an in situ gelling, dry powder vaccine. Vaccine 29: 5221-5231. doi:10.1016/j.vaccine.2011.05.027. PubMed: 21640778.
9. Duizer E, Schwab KJ, Neill FH, Atmar RL, Koopmans MP, et al. (2004) Laboratory efforts to cultivate noroviruses. J Gen Virol 85: 79-87. doi:10.1099/vir.0.19478-0. PubMed: 14718622.
10. Jiang X, Wang M, Graham DY, Estes MK, (1992) Expression, self-assembly, and antigenicity of the norwalk virus capsid protein. J Virol 66: 6527-6532. PubMed: 1328679.
11. Glass RI, Parashar UD, Estes MK, (2009) Norovirus gastroenteritis. N Engl J Med 361: 1776-1785. doi:10.1056/NEJMra0804575. PubMed: 19864676.
12. Lindesmith LC, Beltramello M, Donaldson EF, Corti D, Swanstrom J, et al. (2012) Immunogenetic mechanisms driving norovirus GII.4 antigenic variation. PLOS Pathog 8: e1002705. PubMed: 22615565.
13. Bok K, Abente EJ, Realpe-Quintero M, Mitra T, Sosnovtsev SV, et al. (2009) Evolutionary dynamics of GII.4 noroviruses over a 34-year period. J Virol 83: 11890-11901. doi:10.1128/JVI.00864-09. PubMed: 19759138.
14. Siebenga JJ, Vennema H, Zheng DP, Vinjé J, Lee BE, et al. (2009) Norovirus illness is a global problem: Emergence and spread of norovirus GII.4 variants, 2001-2007. J Infect Dis 200: 802-812. doi:10.1086/605127. PubMed: 19627248.
15. Hansman GS, Natori K, Shirato-Horikoshi H, Ogawa S, Oka T, et al. (2006) Genetic and antigenic diversity among noroviruses. J Gen Virol 87: 909-919. doi:10.1099/vir.0.81532-0. PubMed: 16528040.
16. Wyatt RG, Dolin R, Blacklow NR, DuPont HL, Buscho RF, et al. (1974) Comparison of three agents of acute infectious nonbacterial gastroenteritis by cross-challenge in volunteers. J Infect Dis 129: 709-714. doi:10.1093/infdis/129.6.709. PubMed: 4209723.
17. Herbst-Kralovetz M, Mason HS, Chen Q, (2010) Norwalk virus-like particles as vaccines. Expert Rev Vaccines 9: 299-307. doi:10.1586/erv.09.163. PubMed: 20218858.
18. Vinjé J, (2010) A norovirus vaccine on the horizon? J Infect Dis 202: 1623-1625. doi:10.1086/657088. PubMed: 20979457.
19. Atmar RL, Estes MK, (2012) Norovirus vaccine development: Next steps. Expert Rev Vaccines 11: 1023-1025. doi:10.1586/erv.12.78. PubMed: 23151158.
20. Tate JE, Burton AH, Boschi-Pinto C, Steele AD, Duque J, et al. (2012) 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: A systematic review and meta-analysis. Lancet Infect Dis 12: 136-141. doi:10.1016/S1473-3099(11)70253-5. PubMed: 22030330.
21. Tate JE, Panozzo CA, Payne DC, Patel MM, Cortese MM, et al. (2009) Decline and change in seasonality of US rotavirus activity after the introduction of rotavirus vaccine. Pediatrics 124: 465-471. doi:10.1542/peds.2008-3528. PubMed: 19581260.
22. Patel MM, Steele D, Gentsch JR, Wecker J, Glass RI, et al. (2011) Real-world impact of rotavirus vaccination. Pediatr Infect Dis J 30: S1-S5. doi:10.1097/INF.0b013e3181fefa1f. PubMed: 21183833.
23. Cherian T, Wang S, Mantel C, (2012) Rotavirus vaccines in developing countries: The potential impact, implementation challenges, and remaining questions. Vaccine 30 (Suppl 1):: A3-A6. doi:10.1016/j.vaccine.2011.10.007. PubMed: 22520133.
24. Buttery JP, Danchin MH, Lee KJ, Carlin JB, McIntyre PB, et al. (2011) Intussusception following rotavirus vaccine administration: Post-marketing surveillance in the national immunization program in australia. Vaccine 29: 3061-3066. doi:10.1016/j.vaccine.2011.01.088. PubMed: 21316503.
25. Patel MM, López-Collada VR, Bulhões MM, De Oliveira LH, Bautista Márquez A, et al. (2011) Intussusception risk and health benefits of rotavirus vaccination in mexico and brazil. N Engl J Med 364: 2283-2292. doi:10.1056/NEJMoa1012952. PubMed: 21675888.
26. Donato CM, Ch'ng LS, Boniface KF, Crawford NW, Buttery JP,et al (2012) Identification of strains of RotaTeq rotavirus vaccine in infants with gastroenteritis following routine vaccination. J Infect Dis 206: 377-383. doi:10.1093/infdis/jis361. PubMed: 22615314.
27. Hemming M, Vesikari T, (2012) Vaccine-derived human-bovine double reassortant rotavirus in infants with acute gastroenteritis. Pediatr Infect Dis J 31: 992-994. doi:10.1097/INF.0b013e31825d611e. PubMed: 22581224.
28. Estes MK, Kapikian AZ, (2007) Rotaviruses. In: Knipe D, Griffin D, Lamb R, Martin M, Roizman B, eds. Fields Virology. Lippincott Williams & Wilkins. pp. pp. 1917-1975.
29. Ward R, (2009) Mechanisms of protection against rotavirus infection and disease. Pediatr Infect Dis J 28: S57-S59. doi:10.1097/INF.0b013e3181826e5e. PubMed: 19252425.
30. Choi AH, McNeal MM, Basu M, Flint JA, Stone SC, et al. (2002) Intranasal or oral immunization of inbred and outbred mice with murine or human rotavirus VP6 proteins protects against viral shedding after challenge with murine rotaviruses. Vaccine 20: 3310-3321. doi:10.1016/S0264-410X(02)00315-8. PubMed: 12213401.
31. McNeal MM, VanCott JL, Choi AH, Basu M, Flint JA, et al. (2002) CD4 T cells are the only lymphocytes needed to protect mice against rotavirus shedding after intranasal immunization with a chimeric VP6 protein and the adjuvant LT(R192G). J Virol 76: 560-568. doi:10.1128/JVI.76.2.560-568.2002. PubMed: 11752147.
32. Bertolotti-Ciarlet A, Ciarlet M, Crawford SE, Conner ME, Estes MK, (2003) Immunogenicity and protective efficacy of rotavirus 2/6-virus-like particles produced by a dual baculovirus expression vector and administered intramuscularly, intranasally, or orally to mice. Vaccine 21: 3885-3900. doi:10.1016/S0264-410X(03)00308-6. PubMed: 12922123.
33. Blutt SE, Warfield KL, Estes MK, Conner ME, (2008) Differential requirements for T cells in viruslike particle- and rotavirus-induced protective immunity. J Virol 82: 3135-3138. doi:10.1128/JVI.01727-07. PubMed: 18184712.
34. Lepault J, Petitpas I, Erk I, Navaza J, Bigot D, et al. (2001) Structural polymorphism of the major capsid protein of rotavirus. EMBO J 20: 1498-1507. doi:10.1093/emboj/20.7.1498. PubMed: 11285214.
35. Ward RL, McNeal MM, (2010) VP6: A candidate rotavirus vaccine. J Infect Dis 202 (Suppl):: S101-S107. doi:10.1086/653556. PubMed: 20684688.
36. Huhti L, Blazevic V, Nurminen K, Koho T, Hytönen VP, et al. (2010) A comparison of methods for purification and concentration of norovirus GII-4 capsid virus-like particles. Arch Virol 155: 1855-1858. doi:10.1007/s00705-010-0768-z. PubMed: 20721592.
37. Fromantin C, Jamot B, Cohen J, Piroth L, Pothier P, et al. (2001) Rotavirus 2/6 virus-like particles administered intranasally in mice, with or without the mucosal adjuvants cholera toxin and escherichia coli heat-labile toxin, induce a Th1/Th2-like immune response. J Virol 75: 11010-11016. doi:10.1128/JVI.75.22.11010-11016.2001. PubMed: 11602741.
38. Tamminen K, Huhti L, Koho T, Lappalainen S, Hytönen VP, et al. (2012) A comparison of immunogenicity of norovirus GII-4 virus-like particles and P-particles. Immunology 135: 89-99. doi:10.1111/j.1365-2567.2011.03516.x. PubMed: 22044070.
39. Rockx B, Baric RS, de Grijs I, Duizer E, Koopmans MP, (2005) Characterization of the homo- and heterotypic immune responses after natural norovirus infection. J Med Virol 77: 439-446. doi:10.1002/jmv.20473. PubMed: 16173019.
40. Nurminen K, Blazevic V, Huhti L, Räsänen S, Koho T, et al. (2011) Prevalence of norovirus GII-4 antibodies in finnish children. J Med Virol 83: 525-531. doi:10.1002/jmv.21990. PubMed: 21264875.
41. Tan M, Fang P, Chachiyo T, Xia M, Huang P, et al. (2008) Noroviral P particle: Structure, function and applications in virus-host interaction. Virology 382: 115-123. doi:10.1016/j.virol.2008.08.047. PubMed: 18926552.
42. Knowlton DR, Spector DM, Ward RL, (1991) Development of an improved method for measuring neutralizing antibody to rotavirus. J Virol Methods 33: 127-134. doi:10.1016/0166-0934(91)90013-P. PubMed: 1658027.
43. Ward RL, Kapikian AZ, Goldberg KM, Knowlton DR, Watson MW, et al. (1996) Serum rotavirus neutralizing-antibody titers compared by plaque reduction and enzyme-linked immunosorbent assay-based neutralization assays. J Clin Microbiol 34: 983-985. PubMed: 8815124.
44. LoBue AD, Lindesmith LC, Baric RS, (2010) Identification of cross-reactive norovirus CD4+ T cell epitopes. J Virol 84: 8530-8538. doi:10.1128/JVI.00727-10. PubMed: 20573810.
45. McNeal MM, Basu M, Bean JA, Clements JD, Choi AH, et al. (2007) Identification of an immunodominant CD4+ T cell epitope in the VP6 protein of rotavirus following intranasal immunization of BALB/c mice. Virology 363: 410-418. doi:10.1016/j.virol.2007.01.041. PubMed: 17337285.
46. Ruggeri FM, Johansen K, Basile G, Kraehenbuhl JP, Svensson L, (1998) Antirotavirus immunoglobulin A neutralizes virus in vitro after transcytosis through epithelial cells and protects infant mice from diarrhea. J Virol 72: 2708-2714. PubMed: 9525588.
47. Lindesmith LC, Donaldson E, Leon J, Moe CL, Frelinger JA, et al. (2010) Heterotypic humoral and cellular immune responses following norwalk virus infection. J Virol 84: 1800-1815. doi:10.1128/JVI.02179-09. PubMed: 20007270.
48. Ghosh MK, Dériaud E, Saron MF, Lo-Man R, Henry T, et al. (2002) Induction of protective antiviral cytotoxic T cells by a tubular structure capable of carrying large foreign sequences. Vaccine 20: 1369-1377. doi:10.1016/S0264-410X(01)00467-4. PubMed: 11818155.
49. Fifis T, Gamvrellis A, Crimeen-Irwin B, Pietersz GA, Li J, et al. (2004) Size-dependent immunogenicity: Therapeutic and protective properties of nano-vaccines against tumors. J Immunol 173: 3148-3154. PubMed: 15322175.
50. White LJ, Hardy ME, Estes MK, (1997) Biochemical characterization of a smaller form of recombinant norwalk virus capsids assembled in insect cells. J Virol 71: 8066-8072. PubMed: 9311906.
51. Someya Y, Shirato H, Hasegawa K, Kumasaka T, Takeda N, (2011) Assembly of homogeneous norovirus-like particles accomplished by amino acid substitution. J Gen Virol 92: 2320-2323. doi:10.1099/vir.0.033985-0. PubMed: 21715601.
52. Chachu KA, LoBue AD, Strong DW, Baric RS, Virgin HW, (2008) Immune mechanisms responsible for vaccination against and clearance of mucosal and lymphatic norovirus infection. PLOS Pathog 4: e1000236. PubMed: 19079577.
53. LoBue AD, Thompson JM, Lindesmith L, Johnston RE, Baric RS, (2009) Alphavirus-adjuvanted norovirus-like particle vaccines: Heterologous, humoral, and mucosal immune responses protect against murine norovirus challenge. J Virol 83: 3212-3227. doi:10.1128/JVI.01650-08. PubMed: 19176631.
54. Reeck A, Kavanagh O, Estes MK, Opekun AR, Gilger MA, et al. (2010) Serological correlate of protection against norovirus-induced gastroenteritis. J Infect Dis 202: 1212-1218. doi:10.1086/656364. PubMed: 20815703.
55. Harrington PR, Lindesmith L, Yount B, Moe CL, Baric RS, (2002) Binding of norwalk virus-like particles to ABH histo-blood group antigens is blocked by antisera from infected human volunteers or experimentally vaccinated mice. J Virol 76: 12335-12343. doi:10.1128/JVI.76.23.12335-12343.2002. PubMed: 12414974.
56. Pulendran B, Ahmed R, (2006) Translating innate immunity into immunological memory: Implications for vaccine development. Cell 124: 849-863. doi:10.1016/j.cell.2006.02.019. PubMed: 16497593.
57. Wilkinson TM, Li CK, Chui CS, Huang AK, Perkins M, et al. (2012) Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med 18: 274-280. doi:10.1038/nm.2612. PubMed: 22286307.
58. Lindesmith L, Moe C, Lependu J, Frelinger JA, Treanor J, et al. (2005) Cellular and humoral immunity following snow mountain virus challenge. J Virol 79: 2900-2909. doi:10.1128/JVI.79.5.2900-2909.2005. PubMed: 15709009.
59. McNeal MM, Stone SC, Basu M, Clements JD, Choi AH, et al. (2007) IFN-gamma is the only anti-rotavirus cytokine found after in vitro stimulation of memory CD4+ T cells from mice immunized with a chimeric VP6 protein. Viral Immunol 20: 571-584. doi:10.1089/vim.2007.0055. PubMed: 18158731.
60. Chen SC, Jones DH, Fynan EF, Farrar GH, Clegg JC, et al. (1998) Protective immunity induced by oral immunization with a rotavirus DNA vaccine encapsulated in microparticles. J Virol 72: 5757-5761. PubMed: 9621034.
61. Feng N, Lawton JA, Gilbert J, Kuklin N, Vo P, et al. (2002) Inhibition of rotavirus replication by a non-neutralizing, rotavirus VP6-specific IgA mAb. J Clin Invest 109: 1203-1213. doi:10.1172/JCI200214397. PubMed: 11994409.
62. Zhou H, Guo L, Wang M, Qu J, Zhao Z, et al. (2011) Prime immunization with rotavirus VLP 2/6 followed by boosting with an adenovirus expressing VP6 induces protective immunization against rotavirus in mice. Virol J 8: 3-: 3-422X-8-3. PubMed: 21205330.
63. Schwartz-Cornil I, Benureau Y, Greenberg H, Hendrickson BA, Cohen J, (2002) Heterologous protection induced by the inner capsid proteins of rotavirus requires transcytosis of mucosal immunoglobulins. J Virol 76: 8110-8117. doi:10.1128/JVI.76.16.8110-8117.2002. PubMed: 12134016.
64. Corthésy B, Benureau Y, Perrier C, Fourgeux C, Parez N, et al. (2006) Rotavirus anti-VP6 secretory immunoglobulin A contributes to protection via intracellular neutralization but not via immune exclusion. J Virol 80: 10692-10699. doi:10.1128/JVI.00927-06. PubMed: 16956954.
65. Coffin SE, Clark SL, Bos NA, Brubaker JO, Offit PA, (1999) Migration of antigen-presenting B cells from peripheral to mucosal lymphoid tissues may induce intestinal antigen-specific IgA following parenteral immunization. J Immunol 163: 3064-3070. PubMed: 10477570.
66. Parez N, Garbarg-Chenon A, Fourgeux C, Le Deist F, Servant-Delmas A, et al. (2004) The VP6 protein of rotavirus interacts with a large fraction of human naive B cells via surface immunoglobulins. J Virol 78: 12489-12496. doi:10.1128/JVI.78.22.12489-12496.2004. PubMed: 15507636.
67. Lappalainen S, Nurminen K, Vesikari T, Blazevic V, (2011) Comparison of B and T cell immune responses induced by two rotavirus oligomeric subviral structures. In: Vaccines for enteric diseases 2011, Cannes, France. Poster presentation.